Biotech entity
pharma is the sole category represented across all 1 tracked stories. RxSight is most often covered alongside Acadia Pharmaceuticals, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention RxSight, all published on February 26, 2026.
Last mentioned: Feb 26, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. RxSight is most often covered alongside Acadia Pharmaceuticals, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention RxSight, all published on February 26, 2026. Each carries 20 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering RxSight. Shared-story counts are live from our verified record — not editorial picks.
Mid-cap biotech and specialty pharma companies are demonstrating strong commercial maturation, led by record-breaking rare disease revenues and strategic consolidation. Key players like Mirum and Acadia are scaling rapidly, while Alkermes’ acquisition of Avadel signals a shift toward aggressive portfolio expansion in the neuroscience space.
RxSight is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
